STUDY PROTOCOL

The Perinatal Adverse events and Special Trends in Cognitive Trajectory (PLASTICITY) - pre-protocol for a prospective longitudinal follow-up cohort study [version 1; peer review: 2 approved]

Laura Hokkanen¹, Jyrki Launes², Katarina Michelsson³

¹Faculty of Behavioural Sciences, Division of Cognitive and Neuropsychology, University of Helsinki, Helsinki, Finland

²Faculty of Medicine, Department of Neurology, University of Helsinki, Helsinki, 00029, Finland

³Children's Hospital, University of Helsinki, Helsinki, 00029, Finland

v1 First published: 14 Feb 2013, 2:50
<https://doi.org/10.12688/f1000research.2-50.v1>
 Latest published: 14 Feb 2013, 2:50
<https://doi.org/10.12688/f1000research.2-50.v1>

Abstract

Prospective follow-up studies on long term effects of pre- and perinatal adverse conditions in adulthood are rare. We will continue to follow the prospective cohort of initially 1196 subjects with predefined at-delivery risk factors out of 22,359 consecutive deliveries during 1971-74 at a single maternity hospital. The risk cohort and 93 controls have been followed up with a comprehensive clinical program at 5, 9, and 16 years of age and by questionnaire at the age of 30 years. Major medical events known to affect the development and growth of the brain, or cognitive functions and personality have been documented. Here we present a pre-protocol for the project, which we will call PLASTICITY, whose aim is to follow consenting subjects and controls into mid-adulthood and beyond, and to explore how the neonatal risk factors modulate neurodevelopmental and neurodegenerative processes such as learning disabilities, ADHD, aging, early onset mild cognitive impairment and even dementia. Our first focus is on the neurological and cognitive outcomes at age 40 years, using detailed neurological, neuropsychological, neuroimaging, genetic, blood chemistry and registry based methods. Results will be expected to offer information on the risk of neurological, psychiatric, metabolic and other medical consequences as well as the need for health and social services at the brink of middle age, when new degenerative phenomena are known to emerge. The evaluation at age 40 years will serve as a baseline for later aging studies. We welcome all comments and suggestions, which we will apply in finalizing details and inviting collaboration.

Keywords

adhd

Open Peer Review

Approval Status

	1	2
version 1
14 Feb 2013	view	view
1. Chiadi Onyike , The Johns Hopkins Hospital, Baltimore, MD, USA		
2. Erin Bigler , Brigham Young University, UT, USA		
Any reports and responses or comments on the article can be found at the end of the article.		

Corresponding author: Laura Hokkanen (laura.hokkanen@helsinki.fi)

Competing interests: No relevant competing interests were disclosed.

Grant information: The first 20 years of the project were supported by the Academy of Finland, Signe and Ane Gyllenberg Foundation, Foundation of Pediatric Research, The Association for Life Insurance Companies, and Rinnekoti Foundation.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2013 Hokkanen L *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Hokkanen L, Launes J and Michelsson K. **The Perinatal Adverse events and Special Trends in Cognitive Trajectory (PLASTICITY) - pre-protocol for a prospective longitudinal follow-up cohort study [version 1; peer review: 2 approved]** F1000Research 2013, 2:50 <https://doi.org/10.12688/f1000research.2-50.v1>

First published: 14 Feb 2013, 2:50 <https://doi.org/10.12688/f1000research.2-50.v1>

Introduction

We present here pre-protocol of the “Perinatal Adverse events and Special Trends In Cognitive Trajectory” (PLASTICITY) study. The study aims to test the hypothesis that perinatal adverse events exert an unexpectedly deleterious effect on the brain at middle and older age. This is a prospective longitudinal at-risk cohort study of a 1971–1974 birth cohort that has been prospectively followed to adulthood¹. Several papers, theses, and book chapters about the findings in children up to the age of 16 years have been published based on this material^{2–11}. Therefore, we know the individuals that are in different outcome groups and etiologies. All consenting subjects are aimed to be studied now in their 40s and throughout their remaining lives at 10 or 5 year intervals.

This paper describes our current plans on how this cohort is to be followed-up. An enormous amount of work has been done in the first decades of this follow-up study of individuals from at-risk deliveries. We feel that the unique opportunity of completing the follow-up of such a cohort from birth to death must not be missed. However, we acknowledge that without collaboration, we cannot achieve all that could and should be done. Therefore, we welcome all comments and suggestions, which we will apply in finalizing the study details and inviting collaboration. While a general schedule is outlined here, the exact timetable will depend on methodological, administrative, and financial decisions.

Background

Antenatal and perinatal risks of infant death or disability are well known. These include intrauterine growth restriction, ischemia/hypoxia/asphyxia¹² due to many reasons, jaundice^{13,14}, infection, drugs and maternal disorders^{15,16}. There is a wealth of general literature about the diagnosis, etiology, treatment, social consequences and individual outcomes, and the range of conditions reaches from mild defects to cerebral palsy, serious cognitive deficits and death^{2,12,17–30}. The incidence of death or considerable disability is 0.2 to 5 out of 1000 live births in hypoxic-ischemic encephalopathy^{31,32}, intrauterine growth restriction^{23,33–36}, or jaundice²¹. The outcome has been improving steadily, e.g. according to the Official Statistics of Finland (<http://tilastokeskus.fi/til/kuol/tau.html>), infant mortality has decreased over 70% from 12.7 by 1000 births in 1971 to 2.7 by 1000 births in 2007.

The timing, type, and severity of the long term consequences of antenatal and perinatal complications have mostly been studied in relatively short follow-up studies^{3,8,9,17,19,23,28,32,33,36–41}. Most of them cover the period up to early school age, with possibly some over-emphasis on cerebral palsy due to its juridical importance in many cases^{42,37}. In studies focusing on cognitive, neuropsychiatric and social performance, the longest follow-up periods currently extend into young adulthood^{33,43,44}. Long term studies report diminished IQ and/or scholarly achievement but these are studies that are either retrospective or rely on data from secondary sources such as tests for conscripts^{13,45,46}. Recent results of a retrospective longitudinal study using more specific cognitive tests indicate impaired psychomotor speed, learning and executive functioning in young adults with very low birth weight^{43,47}. Many very interesting and ambitious longitudinal prospective cohort studies have been started recently (see for instance www.birthcohorts.net) but the subjects in

the actively followed-up prospective birth risk cohorts we are aware of^{48–53} will not reach an age when aging-related changes have a serious effect for decades. To the best of our knowledge, no results of prospective follow-up beyond young adulthood exist to date.

The types and extent of structural abnormalities caused by intrauterine growth restriction and/or asphyxia are well known in seriously disabled children. It has been possible to investigate the more subtle changes in brain structures *in vivo* only relatively recently. So far there are relatively few MRI studies^{25,41,54–60} of children who were exposed to adverse conditions *in utero* or perinatally. However, a wide variety of subtle abnormalities resembling those caused by many diseases in adult life, especially in the brain white matter, have been discovered. The current knowledge about either normal or pathological aging emphasize the role of white matter changes both in degenerative and vascular pathology, e.g. white matter lesions are independent risks in both ischemic stroke, vascular dementia, and also degenerative dementias. The time course of these changes is as yet very poorly known.

The incidence of Attention Deficit Hyperactivity Disorder (ADHD) is known to be higher among the subjects with pre- and perinatal risks^{61,62}. In a recent study, low birth weight, preterm birth, and low Apgar scores were reported to increase the risk of ADHD up to 5-fold⁶³. Other syndromes of childhood developmental disabilities include reading disorder/dyslexia, non-verbal learning disorder, dyscalculia, and disorders of motor coordination; entities that often overlap and coincide. The etiology of many of these developmental disorders involves the interaction of multiple risk and protective factors, both genetic and environmental^{64–66}. Follow-up studies suggest that in a large number of children ADHD persists in adulthood, but the range in the reported frequencies is wide, 5–66%⁶⁷. The symptoms may change during lifespan, hyperactivity becoming less common^{68,69} in adulthood. Prospective follow-up studies spanning into the ages of 30–40 are extremely few and none so far reach beyond 40^{70,71}.

As people reach adulthood and beyond, they become susceptible to the neuronal effects of ageing. Based on both large population based cohorts and clinical follow-up studies, most cognitive scores appear to decline from the age of 45 onwards, with faster decline in older people^{72,73}. Along with the normal ageing process, pathological processes also start evolving, and the distinction is clinically not easy to make. Mild Cognitive Impairment (MCI) refers to a preclinical stage that converts to dementia as the disease progresses^{74,75}. On a clinical level MCI is a useful concept but neuropathologically it is complex and inadequately understood⁷⁶. The classical markers of Alzheimer’s disease (AD) neuropathology start to appear in 40-year-olds⁷⁷ with a clear correlation to cognitive functioning⁷⁸. Terms describing preclinical states of AD (including both “asymptomatic at-risk state for AD” and “presymptomatic AD”) refer to the long asymptomatic stage between the earliest pathogenic events/brain lesions of AD and the first appearance of specific cognitive changes^{79,80}. There is evidence that mid-life levels of cardiovascular risk factors (such as elevated blood pressure, cholesterol and smoking) increase the risk for diseases affecting cognition that emerge 20 years or more after the risk factor is measured⁸¹. The role of the vulnerability factors that have been present from the neonatal period in this progression is not known.

Approximately 8% of all dementia cases are in working age (from 30 to 65 years)⁸² with the estimated prevalence among the 45–64 year age group being 98.1 per 100,000⁸³. In both late and early onset dementias AD is the most common cause but frontotemporal degeneration and hereditary forms of dementia are more prevalent in the early onset group^{82,84}. The significance of rarer and ‘disregarded’ pathologies to late-onset dementias has recently been explored in an epidemiological study⁸⁵ but the neuropathological mechanisms of early onset dementias are not fully understood. The significance of perinatal and early childhood events in relation to MCI and dementia are unknown, although asphyxia and preterm birth are listed as risk factors. Based on statistics only, approximately 300 subjects in our birth cohort will develop dementia^{86,87}.

Rationale

Our aim is to identify and study the type and severity of changes that can be revealed by neurological, cognitive, psychiatric, neuroimaging, and neurophysiological techniques as well as metabolic and genetic analyses in a cohort of subject with predefined neonatal adverse events by means of a careful and lifelong follow-up. The results will be compared to those of peers born healthy to test our hypothesis that birth complications may cause undue damage to the central nervous system at a later age.

The rationale is based on the hypothesis of lowered cognitive reserves following perinatal adverse events which would lead to susceptibility for later damage. The concept of brain reserve is based on the protective potential of anatomical features such as brain size, neuronal density and synaptic connectivity⁸⁸ and it can be seen as passive, postulating that there is a fixed threshold below which functional impairment will occur^{88,89}. In contrast, behavioral brain reserve, or cognitive reserve, is an active construct, suggesting that the brain actively attempts to cope with brain damage by using pre-existing cognitive processes or by enlisting compensatory processes^{89,90}. Cognitive reserve is not fixed at any point in life; instead, complex interactions exist between genetics, environmental influences, and the ability to actively compensate for the effects of pathology. Further, it has been suggested that the possible neural implementation of cognitive reserve be subdivided into two components that can also be studied using neurophysiological methods: neural reserve, which refers to individual differences in cognitive processing paradigms and neural networks that are in use in the brain, and neural compensation, which refers to alterations in cognitive processing networks that may take place in order to cope with brain pathology⁸⁹. The risk cohort serves as a model for studying both the expression of cognitive reserve on later neurological conditions, and for evaluating the neural reserve and compensatory mechanisms.

Cognitive reserve has typically been estimated by means of autobiographical data such as socioeconomic status, occupational complexity, educational level, and mentally stimulating leisure activity, in addition to specific measures of IQ. A considerable number of cohort studies have shown the protective effects of these variables in incident dementia (see reviews^{91–93}). Both exercise and cognitive stimulation regulate factors that may increase neuronal plasticity, and there is evidence to suggest that environmental enrichment might act directly to prevent or slow neurodegenerative disorders and permit normal cognitive functioning even in the presence of brain pathology⁹⁴. Similar modulation probably exists in neurodevelopmental

disorders, and these factors will be included in the study paradigm. **Figure 1** illustrates the rationale of the project PLASTICITY.

Aims and objectives

In the present project, several parallel approaches will be applied.

- 1) **Etiology based approach:** Study the neurological, neuropsychological and neuropsychiatric outcome in adulthood in relation to antenatal- and perinatal events that have been established in follow-up of our subjects (e.g. asphyxia, low birth weight, hyperbilirubinemia, maternal diabetes).
- 2) **Syndrome based approach:** Assess long term effects of commonly recognized neurodevelopmental deficits (such as dyslexia or ADHD), to explore the associated neuropsychological, neurological and neuropsychiatric symptoms in adulthood, and deepen and broaden existing knowledge of such symptoms.
- 3) **MCI at the age of 40:** Recognize the potentially elevated risk for cognitive decline in the group of adults with a history of pre- and perinatal risk factors; to study the prevalence of MCI as well as early onset dementia in the working age. Special emphasis will be given to individuals, who have been diagnosed with asphyxia and/or have white matter findings in MRI.
- 4) **Cognitive follow-up:** Assess how the different developmental deficits and factors affect and transform into different varieties of MCI/dementia during later age (repeated evaluation cycles at the age of 50, 60, 65, 70, 75 etc. years).
- 5) **Radiological follow-up:** Define neuroradiological findings in adults with pre- and perinatal risk factors; to clarify the structural lesions in adulthood and to use this information as a baseline for the MCI/dementia follow-up.
- 6) **Genetic analyses:** Analyze the known risk factors of neurological and psychiatric traits (e.g. APOE, DISC1, COMT, ROBO1 to name a few) to be used as covariants in the assessment of disease risk in the whole cohort; genome-wide association study (GWAS) of clearly defined traits, including dyslexia, specific forms of cognitive decline, MRI parameters (leukoaraiosis, regional atrophy etc.). As medical genetics is at the moment the fastest developing of all modalities, this approach will have to be continuously reevaluated.
- 7) **Metabolic and endocrine effects:** Measure metabolic and endocrine functions to be used as important cofactors in statistical analysis. Previous data suggests that low birth weight, preterm delivery and asphyxia may cause various metabolic effects e.g. diabetes and other endocrine abnormalities. On the other hand, these are known to influence the normal as well as the pathological aging process independently.
- 8) **Protective brain plasticity:** Acknowledge the capacity of the brain for plasticity and neural compensation. The length and type of education, amount of special education and rehabilitation, and participation in cognitively stimulating hobbies, exercise and other activities indicating cognitive enrichment will be assessed. We also aim to test the cognitive reserve hypothesis directly by studying the efficiency of neural networks with evoked potential and functional imaging techniques in a subsample of subjects.

Figure 1. Schematic presentation of the study rationale. Phenotypes of the developmental disorders are suggested to modify the phenotypes of age-related degeneration while individual, genetic and environmental factors interact. Perinatal adverse events may potentially pose a lifelong burden by decreasing the cognitive reserves of the individual. Genetic and epigenetic variables set the framework for both early development and the ageing process. Environmental factors may initiate both a positive and a negative cycle while education and rehabilitation can enhance neural reserves and neural compensation.

- 9) **Adjustment, lifestyle, psychiatric comorbidities and quality of life:** Recognize the potential for psychological and psychiatric concerns. Data from questionnaires will be combined with registry data from national social and health registers as well as with the relevant clinical data.

Design and subjects

The 1971–74 birth risk cohort

The basis of this study is the 1971–1974 birth cohort from a Helsinki metropolitan area maternity hospital (Kätilöopisto hospital) that has been prospectively studied up to adulthood¹. There were 22,359 consecutive births which accounted for approximately 10% of all births in Finland during that time. At birth, 1196 (5.4%) presented with at least one predefined risk, see [Table 1](#).

Of the 1196 infants, 158 died before the age of 5. Additionally, 25 were severely disabled and were excluded from further analyses. At the first follow-up at 5 years, 67 could not be traced and 101 were unable to participate, therefore 845 children (462 boys, 383 girls) were re-assessed (at least 83% of those alive and not severely disabled)³. Asphyxia is defined as any brain damage caused by direct ischemia or ischemia induced inflammatory response. These are the patients who were included in the study according to the criteria above and who simultaneously had objective findings indicating probable inadequate brain blood supply.

At the age of 9 years, 748 children were re-assessed and at the age of 16 years, a survey using a mailed questionnaire about neurode-

Table 1. Number of risk factors at inclusion into the study and at 5 years. First column (at inclusion) lists the total numbers of cases in each risk category; a case may appear in several categories. Second column (at 5 yrs) lists the numbers of cases with one risk factor only, and the number of cases with multiple risk factors is given separately.

	At inclusion (1196 cases)	Examined at 5 yrs (845 cases)
Alive at evaluation	1196	1038
Cases with risk factor		
Birth weight 2000 g or less ¹	317	119
External ventilation	161	21
Apgar <7 at 5 or 15 min	372	138
Neurological symptoms: marked hypotonia, apathy, hyperexcitability, rigidity, convulsions, apnoeic spells	195	55
Hyperbilirubinemia: at least two serum bilirubin values of 340 µmol/l (20 mg/100ml) or more, or blood exchange transfusion	368	257
Hypoglycemia: at least two blood glucose values of 1.67 mmol/l (30 mg/100ml) or less for full term babies and 1.21 mmol/l (22 mg/100ml) or less for preterm babies (less than 37 gestational weeks)	104	38
Diabetic mother, including White A class	93	47
Septic infection, bacteriologically verified	36	7
Cases multiple risk factors		163
Ischemia/asphyxia ²	377	255

¹Note that 2000 g was considered a low birth weight, but 1500 g is used in some analyses.

²Number of cases where significant ischemia/hypoxia was diagnosed after inclusion in the study.

velopmental symptoms was conducted. There were 521 responders. Of these, 142 children were clinically examined (mainly those with observed deficits at the age of 5 or at 9 years). At the age of 30 years, a survey was again conducted and 509 subjects responded.

Details of clinical examination and other assessments are given in [Table 2](#).

Healthy control subjects

A control group of 58 children born in uncomplicated deliveries at the same maternity hospital has been followed from the age of 5, and 111 additional children from the age of 9 years of age. Out of the total 169 control cases, 93 returned the questionnaire at the age of 30 years. The control subjects were born at the same maternity hospital during the study period and mostly attended the same primary schools. Hospital records have been reviewed to confirm absence of any perinatal risk factors.

Enrollment and attrition

Presently, the youngest subjects in the cohort are 39 and the oldest are 42 years of age. A full clinical follow-up will be performed during 2013–14, before the oldest subjects turn 43.

The goal is to enroll as many as possible of the original risk cohort, even if they had not been able to participate in some of the earlier follow-up cycles. All surviving cases in the cohort will be contacted with the exception of the severely disabled and those who did not express consent in the survey at 30. We estimate to be able to recruit at least 60% of the entire surviving risk cohort (n = 1038) for the

clinical assessment, based on the responses of the 509/845 cases who have already consented to follow-up.

The control group included 93 cases at the time of the previous survey and we hope to be able to recruit at least 60. This longitudinal control group is important because they have shared the early life experiences, school and social circumstances with the risk cohort.

For the purposes of future follow-ups, a new control group in addition to the longitudinal controls is needed due to attrition and accumulating differences in social and economic surroundings. The new control group will therefore be recruited from the spouses of the risk cases because they share the current social environment and living conditions.

Attrition is a problem in all longitudinal studies. In Finland, as well as in other Nordic countries, requests to participate in research projects are usually met with a positive attitude and inclusion and dropout rates are known to be quite acceptable⁹⁵. Also, people to be contacted for recruitment are easily found through national registries. Still, specific measures to encourage subjects' motivation to continue in the project are needed. Strategies to increase retention will be actively sought and good examples from ongoing projects will be followed (such as⁴⁹). These include, for instance, lowering the threshold to participate (compensation for travel costs, compensation for lost time, reminders to return questionnaires and flexible schedules for visits), inducing gains and benefits from participating (individual feedback on the medi-

Table 2. Tests and measures used at different phases of the study thus far. See footnote for the complete names of the tests. Group sizes (n), RG = risk cohort group, CG = control group.

	At birth RG n = 1196	5 years RG n = 845 CG n = 58	9 years RG n = 748 CG n = 165	16 years RG n = 521 (142 ¹) CG n = 102 (25 ¹)	30 years RG n = 509 CG n = 93
Maternal perinatal data	smoking diabetes medication blood pressure				
Medical	laboratory parameters		psychosomatic	use of alcohol use of drugs	use of alcohol use of drugs smoking accidents mood diseases medication
Neurology	observational scoring	Bax/structured hearing visus handedness	modif./structured audiometry visus handedness	"Soft signs"/ structured	
Family history	illnesses	illnesses handedness	illnesses handedness		
Social environment	parents' work situation	parents' work situation Security risk scale Social risk scale	parents' work situation Security risk scale Social risk scale	parents' work situation	working history
Motor	observational scoring	Berges-Lezine	TOMI Stott Berges-Lezine Gubbay test	TOMI Stott tapping Luria praxis	
Speech/logopedic		articulation name writing	articulation writing	articulation writing	
Cognitive		ITPA Dubowitz	ITPA WISC	WAIS WMS Benton	
Visual perception		Frostig Goodenough	Goodenough	Clock & map	
Behavioral observation	observational scoring	observational scoring	observational scoring		
Behavior & personality rating			teacher rating	parent rating CBCL YRS	Barkley Scales
School achievement			grades special education needs	grades special education needs	grades education level

ITPA = Illinois Test of Psycholinguistic Abilities, TOMI = Test of Motor Impairment, WISC = Wechsler Intelligence Scale for Children, WAIS = Wechsler Adult Intelligence Scale, WMS = Wechsler Memory Scale, CBCL = Child Behavior Checklist, YSL = The Youth Self Report.

¹attended the clinical examination.

cal results), as well as generating a general sense of availability and openness (websites, dissemination of the general results, contact opportunities via phone and email). Subjects will, however, not be paid for participation.

Methods and outcomes in childhood

Previously collected data

The database contains detailed data about the family's social and economic status, maternal risk factors, family genetic traits, medi-

cal data about delivery and delivery complications, child's growth and medical follow up at 5, 9 and 16 years. Additional Child Health Centre information was collected at the ages of 6 months, 12 months, 18 months, 24 months and 4 years. Surveys have included both parents' and teachers' questionnaires as well as self-reports, such as the Child Behavior Check List (CBCL)⁹⁶ and Youth Self Report (YSR)⁹⁷. A structured neurological assessment of the children was carried out using the Neurodevelopmental Screen developed by Michelsson *et al.*⁴, a modification of the test of Bax and

Whitmore⁹⁸ that also includes items from the Berges-Lezine imitation of gestures as well as Gubbay⁹⁹ test. Other standardized tests and measures used over the course of the follow-up include the Stott Test of Motor Impairment¹⁰⁰, Neurological “Soft signs” in Adolescence¹⁰¹, Dubowitz developmental screening test¹⁰², The Illinois Test of Psycholinguistic Abilities¹⁰³ (ITPA Finnish version¹⁰⁴), Goodenough Draw-a-person test¹⁰⁵, Frostig Developmental Test of Visual Perception¹⁰⁶, subtests from the Wechsler Intelligence Scale for Children¹⁰⁷ (WISC Finnish version¹⁰⁸) and subtests from the Wechsler Adult Intelligence Scale¹⁰⁹ (WAIS Finnish version¹¹⁰). At the age of 16 part of the cohort was also assessed with more detailed neuropsychological instruments including the Benton Visual Memory Test¹¹¹ and subtests from the Wechsler Memory Scale¹¹² (WMS Finnish version¹¹³). **Table 2** shows the various measures categorized by function as well as the age of the subject when tested.

Adult outcome was surveyed with a questionnaire about education and work history, medical and social wellbeing as well as cognitive and psychiatric symptoms at 30 years of age. The questionnaire also included the Barkley Current Symptoms Scale as well as the Childhood Symptoms Scale¹¹.

Medical and neurodevelopmental outcomes by diagnoses

The initial purpose of the study was to follow up newborn children with perinatal risk factors into adolescence to estimate the impact of low birth weight, bilirubin etc. on later development. Outcome measures were divided into 1) Medical, e.g. mortality, major disabilities, anomalies, learning disabilities; 2) Psychometric, e.g. development of the linguistic, cognitive and motor skill as assessed by standardized tests; 3) Achievement based, e.g. school performance, education, and work status; and 4) behavioral and social parameters.

The first results of the prospective follow-up research project were described in 1978¹. Perinatal mortality in the risk cohort was 5.35% and it accounted for 83% of all perinatal deaths in that hospital during the study period 1971–74. Except for hyperbilirubinemia, which was less frequent in 1974, there was no marked change in the risk profile from 1971 to 1974¹, indicating that no major breakthrough in treatment success occurred during that time.

The neurodevelopmental screening test performed at 5 years revealed the highest impairment scores in children with neonatal neurological disorders – which most likely had ischemic etiology – and lowest in those with neonatal septic infections³. After the 5 year assessment, 42% of the children were referred for further assessment and/or rehabilitation measures such as special kindergartens, speech therapy, psychologist assessment or neuropsychiatric rehabilitation in a specialized centre¹¹⁵.

Of the children with a birthweight of 1500 g or less, 50% died during the first 6 months⁶. Of those surviving, 12.3% had severe motor, mental or sensory disabilities and even those without were found to have impaired motor function, speech defects and impaired school achievement more often than the controls⁶. The children with a birth weight of 2000 g or less showed a similar but milder picture: mortality during the first 6 months was 28%, severe disabilities were present in 9%, and those without severe disabilities were found to show more impairment in neurodevelopmental screening

examinations and in psychological and articulatory tests at the age of 5 years compared to controls. According to the teachers’ assessment at the age of 9 years, they were more often in need of special education compared to the controls⁵. Also the children with neonatal hyperbilirubinemia managed less well in neurological and psychological tests at the age of 5 years. They had poorer school grades and more often attended special classes for somatically or mentally disabled at the age of 9 years, but their results were still often better than in the rest of the risk group¹¹. The children born during 1972–73 were analyzed for minor and major congenital anomalies. Those with anomalies were found to perform worse in cognitive and motor tests at the age of 9 compared to the other children in the risk group¹⁰. The number of anomalies in the risk group was comparable with the control group but there were more small for gestational age children in the anomaly group than in the non-anomaly group¹⁰.

Minimal brain dysfunction/ADHD

A specific feature in a longitudinal study such as this one is the change in the diagnostic criteria over the years. The initial aim of the prospective study design was to trace children who showed signs of minimal brain dysfunction (MBD), a term which at the time incorporated both behavioral and learning disturbances and various combinations of deficiencies in perception, language, memory, attention, impulse and motor control^{116,117}. The Diagnostic and Statistical Manual of Mental Disorders (DSM)-II in 1968 included a concept of “hyperkinetic reaction of childhood” and in the following version, DMS-III in 1980, this was substituted with attention-deficit with or without hyperactivity. MBD as a diagnostic or even descriptive term was mostly discarded thereafter.

The prevalence of hyperactivity at the age of 9 was reported to be higher in the study cohort than in the controls¹⁰. When the current DSM-IV criteria were retrospectively applied to the childhood data, it was estimated that the cohort includes 122 cases with ADHD (attention deficit hyperactivity disorder) and their long term outcome will be published separately.

The current DSM-IV recognizes three ADHD subtypes, predominantly inattentive, predominantly hyperactive-impulsive, and a combined subtype. A new version, DSM-V is expected to be published in 2013, and the diagnostic criteria may again change. Old diagnostic groups will be retained in the database but classification of the subjects is constantly updated based on new emerging criteria.

Methods and outcomes in adulthood

Planned measurements in midlife

With the exception of the subgroup with suspected disorders who were contacted at 16, the majority of the cohort subjects have not been clinically evaluated after the age of 9. None have undergone MRI scans. It is therefore essential to thoroughly assess the whole group in order to have exact data on the adult outcome.

In the next cycle of assessment at 40 years of age, we are interested in the long term outcome of the developmental disorders dyslexia and ADHD in particular. We are also interested in whether the perinatal risk factors are associated with acquired neurological disorders. Particularly we want to explore the vascular system of the brain, focusing on the subjects with perinatal asphyxia. Later in midlife, at ages 50

to 60 years, the focus will gradually shift towards neurodegenerative disorders, and the study outline will later be updated accordingly.

The study outcomes, which are considered relevant for the risk group in middle age at 40 years, and also to 50 and 60 years assessment cycles, are outlined in [Table 3](#).

Neurological and medical examination will include e.g. structured neurological history and status, hearing, vision, Mini Mental State Examination (MMSE), cardiovascular status, blood pressure, metabolic indices, measure of head circumference, handedness, dexterity, and body sway.

Psychiatric disorders will be screened by SCID-I¹¹⁸ and SCID-II interviews¹¹⁹. Specific tools for ADHD will include the Conners' Adult ADHD Diagnostic Interview for DSM-IV (CAADID)¹²⁰ or the Diagnostic Interview for Adult ADHD (DIVA)¹²¹.

Neuropsychological assessment at the age of 40 will include a battery of tests for basic visuospatial and visuoconstructive skills, tests for motor praxis and dexterity; tests for phonological processing, naming (Boston naming¹²², Rapid alternating stimulus naming¹²³), reading, and arithmetic; executive function measurements (Trails Making Test, Word Fluency, Tower test and Color Word test, either from Delis–Kaplan Executive Function System¹²⁴ or as stand-alone tests), computerized tests for reaction time and attention (such as Continuous Performance Test¹²⁵ and Attention Network Test¹²⁶), tests for memory (such as Rey Auditory Verbal Learning¹²⁷ and Benton¹¹¹); as well as subtests of the Wechsler tests (WAIS-IV¹²⁸ and WMS-III¹²⁹). There will also be questionnaires for subjective symptoms and mood.

The same or slightly modified battery of tests will later be used in repeated testing. A particular challenge in planning the battery to use in longitudinal studies is the availability of the tests in years to come. The traditional pen and paper tests will be around

Table 3. Outcomes to be investigated in the risk cohort in midlife, and methods to assess them.

Outcome	Foreseeable methods for analysis
ADHD and other learning disabilities	<ul style="list-style-type: none"> • Neuropsychological tests • Registry data harvesting • Psychiatric assessment • Assessment by significant others • Genetic testing
Acquired diseases	<ul style="list-style-type: none"> • Neurological examination • Screening tests e.g. Mini Mental State Examination (MMSE) • MRI • Blood tests targeted for e.g. diabetes and endocrine dysfunction • All other relevant clinical tests for any condition requiring medical attention • Registry data harvesting • Genetic testing
Normal aging	<ul style="list-style-type: none"> • Balance evaluation using body sway measurements • Gait and posture observation • Dexterity tests • Neurological "soft signs" • Screening tests e.g. MMSE
Mild Cognitive Impairment (MCI)	<ul style="list-style-type: none"> • Neuropsychological testing • Specific memory and attention tests • MRI • Functional MRI (fMRI) • Neuronal blood/serum markers • Genetic testing • Cognitive evoked responses with MRI and/or fMRI
Early onset dementia	<ul style="list-style-type: none"> • Neuropsychological testing • MRI • fMRI • Genetic testing • Neuronal blood/serum markers • Screening tests e.g. MMSE • Registry data harvesting • Risk assessment
Cognitive reserve and neural compensation	<ul style="list-style-type: none"> • Registry data harvesting • Interviews at visits • Inquiries and self-assessments • Assessment by significant others • Cognitive evoked responses with MRI and/or fMRI

but newer computerized methods present the risk of being more short-lived in the ever-evolving technology.

Laboratory assessment and genetic analyses cannot all be anticipated at the moment. Blood samples will be taken and stored until genetic analyses (e.g. for *APOE*, *DISC1*, *COMT*, and *ROBO1*) can be performed as a batch process. These are open to discussion and collaboration is actively sought.

Neuroradiological imaging including MRI (T1 and T2 weighted and FLAIR T2 imaging, diffusion imaging with diffusion tensor imaging, angiography, and volume measurements of the hippocampi, corpus callosum, relevant nuclei and other relevant structures that have to be defined ad hoc). Ideally, the MMSE would be scheduled the same day or at least within one week of the neuroradiological imaging session. Brain activity will be measured in selected cases using functional MRI (fMRI), recordings of event related potentials (ERP), electroencephalography (EEG) and magnetoencephalography (MEG).

Registry inquiry In addition to the clinical assessment, health register data will be gathered from the Finnish Social Insurance Institution (Kela) concerning disability benefits, health security, rehabilitation, and unemployment benefits. From the Finnish National Institute for Mental Health and Welfare (THL) register data will be applied concerning diagnoses from the National Hospital Discharge Register.

Measurements at age 65 years and older

Longitudinal data will be collected as long as the subjects are willing to participate. We know from Finnish statistics that the estimated life expectancy for someone having reached 30 years of age in 2003 is 46 years for males and 52 for females¹³⁰. This would mean that the men in this cohort should live up to 76 and the women up to 82 years of age. The project outline will later be updated to include the studies after 65 years of age.

Research group and collaborators

Laura Hokkanen, PhD, professor of clinical neuropsychology, University of Helsinki, is the Principal investigator. Other members of the research group include **Jyrki Launes**, MD, PhD, specialist in neurology, University of Helsinki, **Marja Laasonen**, PhD, Helsinki University Central Hospital, Department of Phoniatrics, **Anna-Mari Tuulio-Henriksson**, PhD, Kela – The Social Insurance Institution of Finland and **Maarit Virta**, PhD, University of Helsinki, Institute of Behavioral Sciences. Master's and doctoral level students will be recruited in the project.

Collaborators at this point include **Kimmo Alho**, Professor of psychology, University of Helsinki, Helsinki Collegium for Advanced Studies and Institute of Behavioural Sciences, **Taina Autti**, MD, PhD, Professor of radiology, University of Helsinki, **Oili Salonen**, MD, PhD, Helsinki University Central Hospital, Department of Radiology, **Sami Leppämäki**, MD, PhD, Helsinki University Central Hospital, Department of Psychiatry, and **Pentti Tienari**, MD, PhD, Helsinki University Central Hospital, Department of Neurology and Biomedicum, University of Helsinki, Molecular Neurology Research Program.

National as well as international collaboration is invited. Please send comments and suggestions to Dr Launes at plasticity@live.fi.

Data analysis and statistical plan

The original database created in 1971 was non-electronic (punched cards). It was later keyed in and analyzed using the BMDP (Statistical Software, Inc 1983). Currently the database is on PASW Statistics, Release Version 18.0.0 (SPSS, Inc.) and Microsoft Excel 2010 and can thus be converted and transported easily. The integrity of the data has been checked during conversions and will undergo continuous error checking both electronically and manually.

Interestingly, the structure of the database reflects the change in the information processing techniques over the past 40 years. Initially, due to the dichotomous nature of the punched card processing, the variables concerning the neonatal period and the first 5 years are mainly stored in a categorical/discrete format. This limits the statistical approaches as non-parametric statistics must be used. This, however, in no way prevents the use of early perinatal data for creating categories and covariants for later analyses.

Another common problem in longitudinal birth cohorts is related to repeated psychometric measures. For example it is impossible to use the same psychological/neuropsychological tests for all age groups. Tests of intelligence for pre-school children, school aged children and adults are different and even though they can be scaled in corresponding distributions centering on the mean IQ of 100, they still are not fully comparable.

For the statistical analysis of new data, commercially available statistical analysis packages will be used. For obvious reasons, the statistical consulting facilities provided by the University of Helsinki will be extensively put to use.

Ethical considerations

Infants in the original database were enrolled with an informed consent by a parent. All studies have been conducted in accordance with the Helsinki declaration and consent has been given at each phase of the follow-up. In 2001 the subjects gave their written consent for future follow-ups.

The ethical review was initially done at the Children's Hospital at the Helsinki University Central Hospital for the follow-up visits at 5, 9 and 16.

In November 2012 the material was handed over to Prof Laura Hokkanen, PhD, by a written agreement by Dr. Katarina Michelson, MD, PhD. A new ethical review for the current project and the new plan as well as inclusion of a new group of researchers will be applied for from the Review Board of the Helsinki and Uusimaa hospital district during the spring of 2013 (Medical Research Act 488/1999). A new invitation letter will be sent out to all participants for consent.

Special care will be taken to respect the autonomy of research subjects, to avoid harm, and to ensure privacy and data protection of the cohort. Identifying information will be handled according to the Finnish Personal Data Act (523/1999).

If a subject is found to have a condition requiring medical attention, he or she will be referred to proper medical services by the responsible physician.

Plans for dissemination of the study outcome

The results will be published in international peer reviewed scientific journals. Open access electronic publications will be preferred. It is expected that a project of this magnitude will gain publicity in national media.

Author contributions

LH is responsible for writing most of the present paper. JL is responsible for the medical details and contributed to writing the present

paper. KM is the intellectual owner and main contributor of the original project and the risk cohort data. She has also reviewed the present paper. All authors have agreed to the final content of the article and to its submission for publication.

Competing interests

No relevant competing interests were disclosed.

Grant information

The first 20 years of the project were supported by the Academy of Finland, Signe and Ane Gyllenberg Foundation, Foundation of Pediatric Research, The Association for Life Insurance Companies, and Rinnekoti Foundation.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Michelsson K, Ylinen A, Saarnivaara A, *et al.*: **Occurrence of risk factors in newborn infants. A study of 22359 consecutive cases.** *Ann Clin Res.* 1978; **10**(6): 334–6.
[PubMed Abstract](#)
2. Michelsson K, Lindahl E: **Relationship between perinatal risk factors and motor development at the ages of 5 and 9 years.** In Kalverboer AF, Hopkins B, & Geuze R (eds), *Motor development in early and later childhood: longitudinal perspectives.* Cambridge University Press, 1993; 266–285.
[Publisher Full Text](#)
3. Michelsson K, Ylinen A, Donner M: **Neurodevelopmental screening at five years of children who were at risk neonatally.** *Dev Med Child Neurol.* 1981; **23**(4): 427–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Michelsson K, Linen A: **A neurodevelopmental screening examination for five-year-old children.** *Early Child Dev Care.* 1987; **29**(1): 9–22.
[Publisher Full Text](#)
5. Michelsson K, Noronen M: **Neurological, psychological and articulatory impairment in five-year-old children with a birthweight of 2000 g or less.** *Eur J Pediatr.* 1983; **141**(2): 96–100.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Michelsson K, Lindahl E, Parre M, *et al.*: **Nine-year Follow-up of Infants Weighing 1 500 g or Less at Birth.** *Acta Paediatr Scand.* 1984; **73**(6): 835–841.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Michelsson K, Donner M, Lindahl E: **Neurodevelopmental screening of 5-year-old children.** *Eur J Pediatr.* 1988; **147**(6): 664–5.
[PubMed Abstract](#)
8. Lindahl E, Michelsson K, Donner M: **Prediction of early school-age problems by a preschool neurodevelopmental examination of children at risk neonatally.** *Dev Med Child Neurol.* 1988; **30**(6): 723–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Lindahl E, Michelsson K, Helenius M, *et al.*: **Neonatal risk factors and later neurodevelopmental disturbances.** *Dev Med Child Neurol.* 1988; **30**(5): 571–89.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Lindahl E, Michelsson K: **Neurodevelopmental significance of minor and major congenital anomalies in neonatal high risk children.** *Neuropediatrics.* 1986; **17**(2): 86–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Michelsson K, Lindahl E, Helenius M, *et al.*: **Five and Nine Year Check up of 314 Children with Neonatal Hyperbilirubinaemia.** *Early Child Dev Care.* 1988; **30**(1–4): 167–180.
[Publisher Full Text](#)
12. Arpino C, Compagnone E, Montanaro ML, *et al.*: **Preterm birth and neurodevelopmental outcome: a review.** *Childs Nerv Syst.* 2010; **26**(9): 1139–49.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Ebbesen F, Ehrenstein V, Traeger M, *et al.*: **Neonatal non-hemolytic hyperbilirubinemia: a prevalence study of adult neuropsychiatric disability and cognitive function in 463 male Danish conscripts.** *Arch Dis Child.* 2010; **95**(8): 583–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Ip S, Chung M, Kulig J, *et al.*: **An evidence-based review of important issues concerning neonatal hyperbilirubinemia.** *Pediatrics.* 2004; **114**(1): e130–e153.
[PubMed Abstract](#)
15. Balsells M, Garcia-Patterson A, Gich I, *et al.*: **Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis.** *J Clin Endocrinol Metab.* 2009; **94**(11): 4284–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Landon MB, Mele L, Spong CY, *et al.*: **The Relationship Between Maternal Glycemia and Perinatal Outcome.** *Obstet Gynecol.* 2011; **117**(2 Pt 1): 218–224.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Marret S, Ancel PY, Marpeau L, *et al.*: **Neonatal and 5-year outcomes after birth at 30–34 weeks of gestation.** *Obstet Gynecol.* 2007; **110**(1): 72–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Anastario M, Salafia CM, Fitzmaurice G, *et al.*: **Impact of fetal versus perinatal hypoxia on sex differences in childhood outcomes: developmental timing matters.** *Soc Psychiatry Psychiatr Epidemiol.* 2012; **47**(3): 455–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Doyle LW: **Long-term neurologic outcome for the very preterm growth-restricted fetus.** *Pediatrics.* 2011; **127**(4): e1048–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Ehrenstein V: **Association of Apgar scores with death and neurologic disability.** *Clin Epidemiol.* 2009; **1**: 45–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Gamaleldin R, Iskander I, Seoud I, *et al.*: **Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia.** *Pediatrics.* 2011; **128**(4): e925–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Glass HC, Glidden D, Jeremy RJ, *et al.*: **Clinical Neonatal Seizures are Independently Associated with Outcome in Infants at Risk for Hypoxic-Ischemic Brain Injury.** *J Pediatr.* 2009; **155**(3): 318–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Johnson S: **Cognitive and behavioural outcomes following very preterm birth.** *Semin Fetal Neonatal Med.* 2007; **12**(5): 363–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Padilla N, Falcón C, Sanz-Cortés M, *et al.*: **Differential effects of intrauterine growth restriction on brain structure and development in preterm infants: a magnetic resonance imaging study.** *Brain Res.* 2011; **1382**: 98–108.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Perlman M, Shah PS: **Hypoxic-ischemic encephalopathy: challenges in outcome and prediction.** *J Pediatr.* 2011; **158**(2 Supp): e51–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Pin TW, Eldridge B, Galea MP: **A review of developmental outcomes of term infants with post-asphyxia neonatal encephalopathy.** *Eur J Paediatr Neurol.* 2009; **13**(3): 224–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Rennie JM, Hagmann CF, Robertson NJ: **Outcome after intrapartum hypoxic ischaemia at term.** *Semin Fetal Neonatal Med.* 2007; **12**(5): 398–407.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Stuart A, Otterblad Olausson P, Källén K: **Apgar scores at 5 minutes after birth in relation to school performance at 16 years of age.** *Obstet Gynecol.*

- 2011; 118(2 Pt 1): 201–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Shankaran S, Pappas A, McDonald SA, *et al.*: **Childhood outcomes after hypothermia for neonatal encephalopathy.** *N Engl J Med.* 2012; 366(22): 2085–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. Van Handel M, Swaab H, de Vries LS, *et al.*: **Long-term cognitive and behavioral consequences of neonatal encephalopathy following perinatal asphyxia: a review.** *Eur J Pediatr.* 2007; 166(7): 645–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 31. Tebartz van EL, Klöppel S, Rauer S: **Voltage-gated potassium channel/LG11 antibody-associated encephalopathy may cause brief psychotic disorder.** *J Clin Psychiatry.* 2011; 72(5): 722–723.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Van Handel M, Swaab H, de Vries LS, *et al.*: **Long-term cognitive and behavioral consequences of neonatal encephalopathy following perinatal asphyxia: a review.** *Eur J Pediatr.* 2007; 166(7): 645–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Zwicker JG, Harris SR: **Quality of life of formerly preterm and very low birth weight infants from preschool age to adulthood: a systematic review.** *Pediatrics.* 2008; 121(2): e366–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Morsing E, Asard M, Ley D, *et al.*: **Cognitive function after intrauterine growth restriction and very preterm birth.** *Pediatrics.* 2011; 127(4): e874–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Mayer C, Joseph KS: **Fetal growth: a review of terms, concepts and issues relevant to obstetrics.** *Ultrasound Obstet Gynecol.* 2013; 41(2): 136–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Elgen I, Sommerfelt K, Ellertsen B: **Cognitive performance in a low birth weight cohort at 5 and 11 years of age.** *Pediatr Neurol.* 2003; 29(2): 111–116.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Freeman RK: **Medical and legal implications for necessary requirements to diagnose damaging hypoxic-ischemic encephalopathy leading to later cerebral palsy.** *Am J Obstet Gynecol.* 2008; 199(6): 585–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Jaddoe VW, van Duijn CM, van der Heijden AJ, *et al.*: **The Generation R Study: design and cohort update 2010.** *Eur J Epidemiol.* 2010; 25(11): 823–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Lloyd BW, Wheldall K, Perks D: **Controlled study of intelligence and school performance of very low-birthweight children from a defined geographical area.** *Dev Med Child Neurol.* 1988; 30(1): 36–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Reid SM, Modak MB, Berkowitz RG, *et al.*: **A population-based study and systematic review of hearing loss in children with cerebral palsy.** *Dev Med Child Neurol.* 2011; 53(11): 1038–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Van Kooij BJ, van Handel M, Nivelstein RA, *et al.*: **Serial MRI and neurodevelopmental outcome in 9- to 10-year-old children with neonatal encephalopathy.** *J Pediatr.* 2010; 157(2): 221–227.e2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Ellenberg JH, Nelson KB: **The association of cerebral palsy with birth asphyxia: a definitional quagmire.** *Dev Med Child Neurol.* 2013; 55(3): 210–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Pyhälä R, Lahti J, Heinonen K, *et al.*: **Neurocognitive abilities in young adults with very low birth weight.** *Neurology.* 2011; 77(23): 2052–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Hack M: **Young adult outcomes of very-low-birth-weight children.** *Semin Fetal Neonatal Med.* 2006; 11(2): 127–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Sorensen HT, Sabroe S, Olsen J, *et al.*: **Birth weight and cognitive function in young adult life: historical cohort study.** *BMJ.* 1997; 315(7105): 401–403.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Ehrenstein V, Pedersen L, Grijsa M, *et al.*: **Association of Apgar score at five minutes with long-term neurologic disability and cognitive function in a prevalence study of Danish conscripts.** *BMC Pregnancy Childbirth.* 2009; 9: 14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Strang-Karlsson S, Andersson S, Paile-Hyvärinen M, *et al.*: **Slower reaction times and impaired learning in young adults with birth weight < 1500 g.** *Pediatrics.* 2010; 125(1): e74–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Reid SM, Modak MB, Berkowitz RG, *et al.*: **A population-based study and systematic review of hearing loss in children with cerebral palsy.** *Dev Med Child Neurol.* 2011; 53(11): 1038–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Jaddoe VW, van Duijn CM, van der Heijden AJ, *et al.*: **The Generation R Study: design and cohort update 2010.** *Eur J Epidemiol.* 2010; 25(11): 823–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Ballot DE, Potterton J, Chirwa T, *et al.*: **Developmental outcome of very low birth weight infants in a developing country.** *BMC pediatr.* 2012; 12: 11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Bassan H, Stolar O, Geva R, *et al.*: **Intrauterine growth-restricted neonates born at term or preterm: how different?** *Pediatr Neurol.* 2011; 44(2): 122–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Iwata S, Nakamura T, Hizume E, *et al.*: **Qualitative brain MRI at term and cognitive outcomes at 9 years after very preterm birth.** *Pediatrics.* 2012; 129(5): e1138–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Munck P, Niemi P, Lapinleimu H, *et al.*: **Stability of cognitive outcome from 2 to 5 years of age in very low birth weight children.** *Pediatrics.* 2012; 129(3): 503–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Lodygensky GA, Seghier ML, Warfield SK, *et al.*: **Intrauterine growth restriction affects the preterm infant's hippocampus.** *Pediatr res.* 2008; 63(4): 438–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Krägeloh-Mann I, Helber A, Mader I, *et al.*: **Bilateral lesions of thalamus and basal ganglia: origin and outcome.** *Dev Med Child Neurol.* 2002; 44: 477–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Boichot C, Mejean N, Gouyon JB, *et al.*: **Biphasic time course of brain water ADC observed during the first month of life in term neonates with severe perinatal asphyxia is indicative of poor outcome at 3 years.** *Magn Reson Imaging.* 2011; 29(2): 194–201.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Iwata S, Nakamura T, Hizume E, *et al.*: **Qualitative brain MRI at term and cognitive outcomes at 9 years after very preterm birth.** *Pediatrics.* 2012; 129: e1138–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Mañeru C, Junqué C, Salgado-Pineda P, *et al.*: **Corpus callosum atrophy in adolescents with antecedents of moderate perinatal asphyxia.** *Brain Inj.* 2003; 17(11): 1003–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. Girard N, Raybaud C, Poncet M: **In vivo MR study of brain maturation in normal fetuses.** *AJNR.* 1995; 16(2): 407–413.
[PubMed Abstract](#)
 60. Prayer D, Brugger PC, Kasprian G, *et al.*: **MRI of fetal acquired brain lesions.** *Eur J Radiol.* 2006; 57(2): 233–49.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Gustafsson P, Källén K: **Perinatal, maternal, and fetal characteristics of children diagnosed with attention-deficit-hyperactivity disorder: results from a population-based study utilizing the Swedish Medical Birth Register.** *Dev Med Child Neurol.* 2011; 53(3): 263–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Strang-Karlsson S, Räikkönen K, Pesonen AK, *et al.*: **Very low birth weight and behavioral symptoms of attention deficit hyperactivity disorder in young adulthood: the Helsinki study of very-low-birth-weight adults.** *Am J Psychiatry.* 2008; 165(10): 1345–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Halmøy A, Klungsøyr K, Skjærven R, *et al.*: **Pre- and perinatal risk factors in adults with attention-deficit/hyperactivity disorder.** *Biol Psychiatry.* 2012; 71(5): 474–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Pennington BF: **From single to multiple deficit models of developmental disorders.** *Cognition.* 2006; 101(2): 385–413.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Grigorenko EL: **The first candidate gene for dyslexia: Turning the page of a new chapter of research.** *Proc Natl Acad Sci U S A.* 2003; 100(20): 11190–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 66. Grigorenko EL, Schreiber HE, Wasserstein J: **Developmental Dyslexia in Adults. Implications for Studies of Its Etiology.** *Adult Learning Disorders. Contemporary issues.* Psychology Press: New York, 2008.
[Reference Source](#)
 67. Biederman J: **Attention-deficit/hyperactivity disorder: a selective overview.** *Biol Psychiatry.* 2005; 57(11): 1215–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Biederman J, Mick E, Faraone SV: **Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.** *Am J Psychiatry.* 2000; 157(5): 816–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. Wilens TE, Biederman J, Spencer TJ: **Attention deficit/hyperactivity disorder across the lifespan.** *Annu Rev Med.* 2002; 53: 113–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Seidman LJ: **Neuropsychological functioning in people with ADHD across the lifespan.** *Clin Psychol Rev.* 2006; 26(4): 466–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Biederman J, Petty CR, Woodworth KY, *et al.*: **Adult outcome of attention-deficit/hyperactivity disorder: a controlled 16-year follow-up study.** *J Clin Psychiatry.* 2012; 73(7): 941–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Salthouse TA: **Decomposing age correlations on neuropsychological and cognitive variables.** *J Int Neuropsychol Soc.* 2009; 15(5): 650–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. Singh-Manoux A, Kivimäki M, Glymour MM, *et al.*: **Timing of onset of cognitive decline: results from Whitehall II prospective cohort study.** *BMJ.* 2011; 344: d7622.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. Petersen RC, Doody R, Kurz A, *et al.*: **Current concepts in mild cognitive impairment.** *Arch Neurol.* 2001; 58(12): 1985–1992.
[PubMed Abstract](#) | [Publisher Full Text](#)

75. Winblad B, Palmer K, Kivipelto M, *et al.*: **Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.** *J Intern Med.* 2004; **256**(3): 240–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Stephan BC, Hunter S, Harris D, *et al.*: **The neuropathological profile of mild cognitive impairment (MCI): a systematic review.** *Mol Psychiatry.* 2012; **17**(11): 1056–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Braak H, Thal DR, Ghebremedhin E, *et al.*: **Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.** *J Neuropathol Exp Neurol.* 2011; **70**(11): 960–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Nelson PT, Alafuzoff I, Bigio EH, *et al.*: **Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.** *J Neuropathol Exp Neurol.* 2012; **71**(5): 362–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. Dubois B, Feldman HH, Jacova C, *et al.*: **Revising the definition of Alzheimer's disease: a new lexicon.** *Lancet Neurol.* 2010; **9**(11): 1118–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Sarazin M, De Souza LC, Lehericy S, *et al.*: **Clinical and research diagnostic criteria for Alzheimer's disease.** *Neuroimaging Clin N Am.* 2012; **22**(1): 23–32, viii.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Launer LJ: **The epidemiologic study of dementia: a life-long quest?** *Neurobiol Aging.* 2005; **26**(3): 335–340.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Luengo-Fernandez R, Leal J, Gray A: **Dementia 2010. The economic burden of dementia and associated research funding in the United Kingdom.** Health Economics Research Centre, University of Oxford, 2010.
[Reference Source](#)
83. Harvey RJ, Skelton-Robinson M, Rossor MN: **The prevalence and causes of dementia in people under the age of 65 years.** *J Neurol Neurosurg Psychiatry.* 2003; **74**(9): 1206–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Snowden JS, Thompson JC, Stopford CL, *et al.*: **The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships.** *Brain.* 2011; **134**(Pt 9): 2478–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Keage HA, Ince PG, Matthews FE, *et al.*: **Impact of less common and "disregarded" neurodegenerative pathologies on dementia burden in a population-based cohort.** *J Alzheimers Dis.* 2012; **28**(2): 485–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
86. Seshadri S, Wolf PA, Beiser A, *et al.*: **Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study.** *Neurology.* 1997; **49**(6): 1498–504.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Ott A, Breteler MM, Van Harskamp F, *et al.*: **Incidence and risk of dementia. The Rotterdam Study.** *Am J Epidemiol.* 1998; **147**(6): 574–80.
[PubMed Abstract](#)
88. Satz P: **Brain reserve capacity on symptom onset after brain injury: A formulation and review of evidence for threshold theory.** *Neuropsychology.* 1993; **7**: 273–295.
[Reference Source](#)
89. Stern Y: **Cognitive reserve.** *Neuropsychologia.* 2009; **47**(10): 2015–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Stern Y: **What is cognitive reserve? Theory and research application of the reserve concept.** *J Int Neuropsychol Soc.* 2002; **8**(3): 448–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
91. Fratiglioni L, Wang HX: **Brain reserve hypothesis in dementia.** *J Alzheimers Dis.* 2007; **12**(1): 11–22.
[PubMed Abstract](#)
92. Valenzuela MJ, Sachdev P: **Brain reserve and dementia: a systematic review.** *Psychol Med.* 2006; **36**(4): 441–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Valenzuela MJ, Sachdev P: **Brain reserve and cognitive decline: a non-parametric systematic review.** *Psychol Med.* 2006; **36**(8): 1065–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Petrosini L, De Bortolo P, Foti F, *et al.*: **On whether the environmental enrichment may provide cognitive and brain reserves.** *Brain Res Rev.* 2009; **61**(2): 221–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
95. Olsen J, Melbye M, Olsen SF, *et al.*: **The Danish National Birth Cohort--its background, structure and aim.** *Scand J Public Health.* 2001; **29**(4): 300–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. Achenbach TM, Edelbrock CS: **Manual for the Child Behavior Checklist and Revised Child Behavior Profile.** University of Vermont Department of Psychiatry: Burlington, VT, 1983; 230.
[Reference Source](#)
97. Achenbach TM, Edelbrock CS: **Manual for Youth Self-Report and Profile.** University of Vermont Department of Psychiatry: Burlington, VT, 1987; 212.
[Reference Source](#)
98. Bax M, Whitmore K: **Neurodevelopmental screening in the school-entrant medical examination.** *Lancet.* 1973; **2**(7825): 368–370.
[PubMed Abstract](#) | [Publisher Full Text](#)
99. Gubbay SS: **The Clumsy Child. Major Problems in Neurology No 5.** WB Saunders Co Ltd: London, 1975.
[Reference Source](#)
100. Stott DH, Moyes FA, Henderson SA: **A Test of Motor Impairment.** Brook Educational: Guelph, Ontario, 1972.
101. Stokman CJ, Shafer SQ, Shaffer D, *et al.*: **Assessment Of Neurological "Soft Signs" In Adolescents: Reliability Studies.** *Dev Med Child Neurol.* 1986; **28**(4): 428–439.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Dubowitz LMS, Leibowitz D, Goldberg C: **A Clinical Screening Test for Assessment of Intellectual Development in Four and Five-year-old Children.** *Dev Med Child Neurol.* 1977; **19**(6): 776–782.
[Publisher Full Text](#)
103. Kirk SA, McCarthy JJ, Kirk WD: **The Illinois Test of Psycholinguistic Abilities.** Revised edition, University of Illinois Press: Urbana, IL, 1968.
[Reference Source](#)
104. Kuusinen J, Bläfield L: **Illinois Test of Psycholinguistic Abilities. Examiner's manual.** University of Jyväskylä: Jyväskylä, 1974.
[Reference Source](#)
105. Goodenough F: **Measurement of intelligence by drawings.** World Company: New York, 1926.
106. Frostig M, Lefevre W, Whittlesey JRB: **Administration and Scoring Manual for the Marianne Frostig Test of Visual Perception.** Consulting Psychologists Press: Palo Alto, California, 1966; 40.
[Reference Source](#)
107. Wechsler D: **Wechsler Intelligence Scale for Children.** Psychological Corporation: New York, 1949.
[Reference Source](#)
108. Wechsler D: **[Wechsler Intelligence Scale for Children. Manual].** Psykologien Kustannus OY: Helsinki, 1971.
[Reference Source](#)
109. Wechsler D: **Wechsler Adult Intelligence Scale.** The Psychological Corporation: New York, 1955.
110. Wechsler D: **[Wechsler adult intelligence scale. WAIS manual].** Psykologien Kustannus OY: Helsinki, 1970.
111. Benton A: **The Revised Visual Retention Test.** The Psychological Corporation: New York, 1974; 4.
112. Wechsler DA: **A Standardized memory scale for clinical use.** *J Psychology.* 1945; **19**(1): 87–95.
[Publisher Full Text](#)
113. Wechsler D: **[Wechsler memory scale. WMS manual].** Psykologien Kustannus OY: Helsinki, 1975.
114. Barkley RA, Murphy KR: **Attention-Deficit Hyperactivity Disorder: A Clinical Workbook (2nd. ed).** The Guilford Press: New York, 1998.
[Reference Source](#)
115. Lindahl E, Michelsson K, Donner M: **Prediction of early school-age problems by a preschool neurodevelopmental examination of children at risk neonatally.** *Dev Med Child Neurol.* 1988; **30**(6): 723–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
116. Clements SD: **Minimal brain dysfunction in children: Terminology and identification. (NINDB monograph no. 3).** U.S. Dept. of Health, Education and Welfare, NINDB.: Washington, DC, 1966.
[Reference Source](#)
117. Hagberg B: **[Minimal brain dysfunction--what does it imply in child development and adaptation].** *Läkartidningen.* 1975; **72**(36): 3296–300.
[PubMed Abstract](#)
118. First MB, Spitzer RL, Gibbon M, *et al.*: **Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV).** American Psychiatric Press: Washington DC, 1996.
119. First MB, Gibbon M, Spitzer RL, *et al.*: **Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II).** American Psychiatric Press: Washington DC, 1997; 41.
[Reference Source](#)
120. Epstein JN, Johnson DE, Conners CK: **Conners' Adult ADHD Diagnostic Interview for DSM-IV (CAADID).** Multi-Health Systems: Toronto, 2001.
[Reference Source](#)
121. Kooij JJS: **Adult ADHD. Diagnostic assessment and treatment.** 3rd ed., Springer, 2013.
[Publisher Full Text](#)
122. Kaplan E, Goodglass H, Weintraub S: **Boston Naming Test.** Waverly, Inc., Baltimore 1983.
123. Wolf M: **Rapid alternating stimulus naming in the developmental dyslexias.** *Brain Lang.* 1986; **27**(2): 360–379.
[PubMed Abstract](#) | [Publisher Full Text](#)
124. Delis DC, Kaplan E, Kramer JH: **Delis Kaplan Executive Function System (D-KEFS).** The Psychological Corporation: San Antonio, TX, 2001.
[Reference Source](#)
125. Conners CK, MHS Staff (Eds.) **Conners' Continuous Performance Test II Computer Program for Windows Technical Guide and Software Manual.**

Multi-Health Systems: North Tonawanda, NY 2000.

[Reference Source](#)

126. Fan J, McCandliss BD, Sommer T, *et al.*: **Testing the Efficiency and Independence of Attentional Networks.** *J Cogn Neurosci.* 2002; **14**(3): 340–347.
[PubMed Abstract](#) | [Publisher Full Text](#)
127. Lezak MD: **Neuropsychological assessment.** Oxford University Press: New York 1995; 1056.
[Reference Source](#)

128. Wechsler D: **WAIS-IV - Wechsler Adult Intelligence Scale - IV.** Pearson, Psykologien Kustannus OY Helsinki, 2012.
[Reference Source](#)

129. Wechsler D: **Wechsler adult intelligence scale - third edition: Manual.** Pearson, Psykologien Kustannus OY Helsinki 2005.

130. **OSF Statistics Finland - Life expectancy in 1983 and 2003.** *Official Statistics of Finland (OSF): Causes of death, 2003.*
[Reference Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 27 August 2013

<https://doi.org/10.5256/f1000research.950.r1274>

© 2013 Bigler E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Erin Bigler

Department of Psychology, Brigham Young University, UT, USA

With the improvements in managing adverse events that occur during the perinatal period, infants that would not have survived given medical and obstetrical care prior to the 1970's now survive. Although cognitive and neurobehavioral sequelae are commonplace in children who experience adverse perinatal effects, almost all studies that have addressed such problems have been based on select sub-samples, including small N and anecdotal studies. Larger outcome studies often get allocated to one particular type of adverse perinatal even like asphyxia. The uniqueness the study design presented by Hokkanen, Launes and Michelsson is to include all "adverse" perinatal events and prospectively follow this cohort throughout life. In this study from a single maternity hospital, 1196 subjects met inclusion criteria for perinatal adverse events from a consecutive sample of 22, 359. In that these subjects were enrolled from 1971 through 1974 means they are now reaching their 40's. The other by-product of improved healthcare of the 20th and 21st centuries is that once born, longevity is now the expectation with survival well beyond 78 years of age the norm. Because of this and the potential for those who suffer perinatal adverse events to have increased risk for a host of neurological, neuropsychiatric, cognitive and behavioral effects, it has become very important to better understand how these perinatal influences affect long-term outcome. Much of the past research has merely focused on the transition from surviving the adverse event and its influence on childhood and then the transition to adulthood. This proposed study is truly a lifespan study with a single cohort that experienced adverse perinatal events.

In this well thought-out and written study design, Hokkanen and colleagues capitalize on a single cohort of births in Finland where prospectively acquired medical, neurological, developmental, educational and neuropsychological test information has been previously obtained and the current proposed design will capture this cohort in their 40's. All fields of medicine and psychology have improved in major ways since the 1970s with improved assessment methods and a more comprehensive understanding of how early brain insult may affect function and how it should be measured. As outlined in Figure 1, Hokkanen *et al.* show the potential interactive nature of numerous relations between neurodevelopmental disorders and later-in-life neurodegenerative disorders. Previously not assumed to be a factor in aging and the development of degenerative

diseases like Alzheimer's, early events are now known to participate in the overall cognitive and brain reserve of the individual. Certain factors may predispose to degeneration yet other factors may relate to plasticity and resiliency. Potentially, the only way some of these factors could be teased out is through long-term prospective studies as proposed by Hokkanen *et al.* Inexorably this cohort will march on to their 60's and beyond and tracking their progress may provide immeasurable insights into what are critical vulnerability factors that predispose to mild cognitive impairment and transition to dementia. Hokkanen *et al.* nicely detail the major factors for data extraction as well as attrition. Table 3 outlines the specific outcome areas that will be targeted and methods to examine outcome. One of the critical improvements since this cohort was first identified is the development in neuroimaging. As outlined in Table 3, MRI including functional MRI studies will be obtained.

This manuscript is very well written. The questions raised, the uniqueness of this cohort, the ability to answer not only some long-term developmental questions in terms of outcome, but also aging and risk for dementia merely point out how incredibly unique is this cohort. I very much like the acronym – PLASTICITY. This has been and will be a most important and valuable clinical research cohort to study and will help answer questions about vulnerability as well as resiliency in brain development and aging.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 08 March 2013

<https://doi.org/10.5256/f1000research.950.r820>

© 2013 Onyike C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chiadi Onyike

Frontotemporal Dementia and Young-Onset Dementias Clinic, The Johns Hopkins Hospital, Baltimore, MD, USA

The Perinatal Adverse events and Special Trends in Cognitive Trajectory (PLASTICITY) - pre-protocol for a prospective longitudinal follow-up cohort study is rather intriguing. By observing a well-developed cohort of individuals who suffered perinatal adversity as they enter mid-life and later-life, this study can provide valuable insights into the long-term effects of perinatal adversity on the cognitive, behavioural and functional prospects of the individual. The findings would also be valuable from a neuropsychiatry research perspective, as it offers examination of perinatal and psychosocial risk factors of mid-life and late-life dementia, cognitive decline and psychiatric disorder. Already, some data suggest that learning disabilities are associated with a higher risk for frontotemporal dementia in later life (see Rogalski *et al.*, 2008). Thus this is an excellent and timely study, and the research agenda offers examination of many important questions. As with all major undertakings, the devil is in the details. One would eventually want to see the details, i.e., the

measurement and data analysis procedures. I am especially interested in understanding how the data analysis will manage intervening events such as adverse rearing environment, head trauma, substance abuse, that may have potential for independent or overriding influence on the outcomes.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research